Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies

• Published in: BMJ open Vol. 11; no. 7; p. e047717
• Main Authors: Noori, Atefeh, Miroshnychenko, Anna, Shergill, Yaadwinder, Ashoorion, Vahid, Rehman, Yasir, Couban, Rachel J, Buckley, D Norman, Thabane, Lehana, Bhandari, Mohit, Guyatt, Gordon H, Agoritsas, Thomas, Busse, Jason W
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 28.07.2021; BMJ Publishing Group
• Series: Original research
• Subjects: Analgesics, Opioid - therapeutic use; Bias; Cannabinoids - therapeutic use; Chronic pain; Chronic Pain - drug therapy; General practice / Family practice; Humans; Medical marijuana; Medical Marijuana - therapeutic use; Meta-analysis; Narcotics; Observational studies; Observational Studies as Topic; Pain; Patients; Randomized Controlled Trials as Topic; Signal transduction; Systematic review; Tetrahydrocannabinol; THC; Vomiting; cancer pain; pain management; general medicine (see internal medicine)
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2020-047717

ObjectiveTo assess the efficacy and harms of adding medical cannabis to prescription opioids among people living with chronic pain.DesignSystematic review.Data sourcesCENTRAL, EMBASE and MEDLINE.Main outcomes and measuresOpioid dose reduction, pain relief, sleep disturbance, physical and emotional functioning and adverse events.Study selection criteria and methodsWe included studies that enrolled patients with chronic pain receiving prescription opioids and explored the impact of adding medical cannabis. We used Grading of Recommendations Assessment, Development and Evaluation to assess the certainty of evidence for each outcome.ResultsEligible studies included five randomised trials (all enrolling chronic cancer-pain patients) and 12 observational studies. All randomised trials instructed participants to maintain their opioid dose, which resulted in a very low certainty evidence that adding cannabis has little or no impact on opioid use (weighted mean difference (WMD) −3.4 milligram morphine equivalent (MME); 95% CI (CI) −12.7 to 5.8). Randomised trials provided high certainty evidence that cannabis addition had little or no effect on pain relief (WMD −0.18 cm; 95% CI −0.38 to 0.02; on a 10 cm Visual Analogue Scale (VAS) for pain) or sleep disturbance (WMD −0.22 cm; 95% CI −0.4 to −0.06; on a 10 cm VAS for sleep disturbance; minimally important difference is 1 cm) among chronic cancer pain patients. Addition of cannabis likely increases nausea (relative risk (RR) 1.43; 95% CI 1.04 to 1.96; risk difference (RD) 4%, 95% CI 0% to 7%) and vomiting (RR 1.5; 95% CI 1.01 to 2.24; RD 3%; 95% CI 0% to 6%) (both moderate certainty) and may have no effect on constipation (RR 0.85; 95% CI 0.54 to 1.35; RD −1%; 95% CI −4% to 2%) (low certainty). Eight observational studies provided very low certainty evidence that adding cannabis reduced opioid use (WMD −22.5 MME; 95% CI −43.06 to −1.97).ConclusionOpioid-sparing effects of medical cannabis for chronic pain remain uncertain due to very low certainty evidence.PROSPERO registration numberCRD42018091098.